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Abstract
Obesity is a growing problem in the United States, though not a new one. It was estimated that
over 72 million U.S. adults alone have a diagnosis of obesity. Among all preventable premature deaths,
obesity ranks as the second leading cause. Contemporary classifications define obesity as a body mass
index (BMI) greater than or equal to 30. Several common comorbidities are widely present in obese
populations, particularly hypertension, diabetes, and hyperlipidemia. Among these chronic disease
states, hypertension has been identified as the most common and earliest identifiable. The purpose of
this study was to make inferences on the prescribing of antihypertension medications in an obese
population, as well as the associated cost of said medications. Cerner’s Health Facts Library, a health
records library that contains de-identified patient information was employed for this study. Structured
Query Language (SQL) was used to design tables that incorporated all relevant and necessary
information for analysis of the study question. The results of this study showed that ACE inhibitors were
the most commonly prescribed blood pressure lowering class of medication in this obese population. Of
this class, the ACE inhibitor lisinopril was the most commonly prescribed. Lisinopril was also identified as
the cheapest ACE inhibitor.
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Chapter 1
Introduction
The prevalence of obesity, classified as a BMI greater than 30 (Table 1), has reached epidemic
proportions. A study by Ogden et al. estimated that over 72 million US adults alone have a diagnosis of
obesity (Ogden et al. 2007). Additionally, among all preventable premature deaths, obesity ranks as the
second leading cause, with smoking holding on to the number one spot (Stein & Colditz, 2004).
However, some experts have predicted that obesity may soon replace smoking as the leading cause of
preventable deaths in the United States. Since the World Health Organization (WHO) classified obesity
as a disease, various initiatives have been implemented to attempt to tackle the growing issue of
obesity. However, the prevalence has not decreased, and therefore, remains an important public health
agenda (WHO, 2016). Interestingly, the prevalence of obesity differs by sex, age, and socioeconomic
status, with a rapid increase in the occurrence of obesity among younger populations and those of lower
socioeconomic status. Obesity has been and continues to be a major public health issue both in itself
and as a result of its association with the development of several chronic comorbidities (NIH, 2006).
The steady increase in the prevalence of obesity has created a growing need and demand for a
more in-depth focus on preventable cardiovascular diseases. Such initiatives would target the most
common comorbidities associated with obesity. Such initiatives would also pay special attention to
disease states such as diabetes mellitus, hyperlipidemia, and hypertension. This is because obesity is
associated with an increased incidence of cardiovascular disease, type 2 diabetes mellitus, hypertension,
stoke, dyslipidemia (hyperlipidemia), osteoarthritis, and some cancers (Burton et al. 2005). Of the top
three comorbid conditions, diabetes, hyperlipidemia, and hypertension, hypertension is the most
common.

6

AN ASSESSMENT OF UTILIZAITON OF PRESCRIPTION
Table 1. Weight Classifications by Body Mass Index (BMI)
Terminology

BMI (kg/m2) Range

WHO Classification

Underweight

<18.5

Underweight

Normal

18.5-24.9

Normal

Overweight

25.0-29.9

Preobese

Obesity Class 1

30.0-34.9

Obese Class 1

Obesity Class 2

35.0-39.9

Obese Class 2

Obesity Class 3

> 40

Obese Class 3

Background of Problem
A study published by Wang and Ling in 2008 looked at the cost and prevalence of obesity in the
United States and found some interesting results. This study found that the annual spending related to
obesity and its associated comorbidities was estimated at $315.8 billion dollars in 2010, accounting for
27.5% of the United States healthcare expenditure. Additionally, they concluded that costs related to
being overweight or obese are projected to reach $861 billion dollars by 2030 (Wang and Ling, 2008).
This is a significant portion of U.S. healthcare cost and therefore warrants a closer analysis. This led us to
breakdown the numbers and assess the role that medications play in contributing to the rising cost of
care for obese populations, and any implications that may be revealed by what was find.
Purpose of Study
With the idea of the enormous cost associated with care for obese and overweight populations
in mind, we wanted to determine the role that prescription medications played in contributing to the
overall cost and burden of obesity on the U.S. healthcare system. This study determined the most
common comorbid conditions associated with obesity and broke them down further into the most
common and earliest identifiable comorbid condition. This was found to be hypertension. The aim of

7

AN ASSESSMENT OF UTILIZAITON OF PRESCRIPTION
this study was to determine which hypertension medications were most commonly prescribed in obese
patients, the cost associated with each and to infer how medication cost affects the delivery and quality
of care administered.

Significance of Study
The focus of this study, as mentioned above, is to determine the most frequently, and most
expensive hypertension medications prescribed. This study is important because the prevalence of
obesity is at an all time high in the United States and continues to grow. This study breaks down the
most frequently prescribed hypertension medications and assess the cost associated with each. This is
significant because hypertension is the most common comorbid condition associated with obesity, as
well and the earliest identifiable risk factor. By indirectly assessing prescribing, and cost, we can draw
inferences and make associations between the medications prescribed, disease progression, and
compare the most updated treatment guidelines with what is actually being prescribed. This type of
analysis has the ability to generate hypothesis and shed light on any inconsistencies.
In addition to the aforementioned, this research has the ability to affect populations at risk for
obesity. This is important, because the cost associated with obesity in 2010 was at $315.8 billion dollars,
and it is estimated that the cost will be $861 billion dollars by 2030 (Wang and Ling, 2008). By shedding
light on cost, and prescribing, and comparing that to current recommended evidence-based treatment
guidelines, this study can generate discussion on the way hypertension in currently managed in the
obese.
Research Questions
As mentioned above, the questions that this paper aims to answer are important ones. These
include determining which hypertension medications are most commonly prescribed (occur the most
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frequently) and determining which hypertension medications are the most expensive. To answer these
questions, this study relied on Cerner’s Health Facts® Database. This database captures and stores deidentified, longitudinal electronic health record (EHR) patient data, and then aggregates and organizes
these data into consumable data sets to facilitate analysis and reporting. The data are generated from
Cerner and non-Cerner participating contributing facilities and go back as far as 2000 (USC, 2017). For
the purposes of this paper, we will only review the calendars years of 2016 and 2017 due to the lack of
manpower and resources to analyze larger amounts of data. Oracle will be used to create queries that
allow us to analyze the data in Cerner’s database. Simple queries will be written that identify the most
commonly prescribed medications for the time period that we are interested in. This information will be
broken down further to analyze the cost of each hypertension medication. By doing this, it will allow for
analysis of prescribing and cost. With this information, inferences can be made regarding the delivery of
care as well as how evidence-based and appropriate the care is.
Definition of Terms
Antihypertensives – A class of medications used to treat hypertension (high blood pressure). The
goal of this therapy is to prevent the complications associated with prolonged high blood pressure.
Angiotensin Converting Enzyme Inhibitor (ACE Inhibitor) – A class of antihypertensive
medications that lower blood pressure by inhibiting the enzyme, ACE.
Calcium Channel Blocker (CCB) - A class of antihypertensive medications that lower blood
pressure by antagonizing the movement of calcium through calcium channels.
Total Charges - The total charges for an encounter. Total Charges includes both covered and
non-covered charges.
Unit Price - The price per dose for inpatient orders, or the price of the entire quantity for
outpatient orders.
9
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Limitations
As with every research study, there are limitations. Because this research question relies on
information entered into an electronic health record, the data is only as accurate as it was entered.
Inaccurate entries and coding are two limitations of this study. Additionally, not all relevant information
may have been available for analysis due to clerical entering and editing. Additional limitations include
the fact that this study only assess the years of 2016 and 2017 leading to a smaller sample size. This may
limit external validity.
Chapter 2
Review of Literature
This section will focus on how the literature was obtained, as well as a brief history on the
current research question, with a focus on past, and present literature. Each article referenced in this
study will be briefly reviewed and related to the overall purpose of this study.
Search engines employed in this literature review included PubMed, Google Scholar, and the
Cochrane Library. Terms such as “obesity” “hypertension” “comorbidities” “obesity disease burden” and
“pharmacoeconomics of obesity” were all used to begin the literature search. Of the literature search
engines above, PubMed provided the most relevant results, and therefore, provided the most articles
included in this paper. Google Scholar provided the broadest information sources and set a solid
foundation that allowed for better understanding of the subject. Articles included in this paper were not
limited by date published. To further narrow the search, articles had to be US-based, of high-quality
study design, and contain large sample sizes. No case-controlled studies were included in this paper.
Once the most relevant articles were identified, they were analyzed for accurateness. Of the top 15
most relevant articles identified, 2 were studied in a Korean population, 1 included a UK population
sample, 1 was a poorly designed case study and 1 included a handicap population consisting of
paraplegics and quadriplegics. As a result, only 10 articles were included in the final analysis. As
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mentioned earlier, publication dates were not limited. This was done to provide historical context and
reference for the researchers and audience.
To provide historical reference, literature on the topic of obesity and the disease burden
associated with it is vast and thorough. This includes classification of obesity, disease progression,
associated comorbidities, predisposing factors, prevalence, genetic associations, pharmacoeconomic
analysis, and medications used to treat, among many others. However, despite all of the research done
on this topic, there is a limited amount of studies that breakdown the most commonly prescribed
medications and assess the associated cost and prescribing. Furthermore, there are even fewer studies
that assess specific classes of medications (i.e. antihypertensives). A 1993 study by Schmieder, Gatzka,
Schächinger, Schobel, and Rüddel looked at the use of different types of antihypertensives in obesity,
with the hypothesis that beta blockers are more effective in this population than calcium channel
blockers. They believed that calcium channel blockers would be more effective in a non-obese
population (Schmieder et al. 1993). While not identical to this study, this is one of the few studies that
assess the use of different hypertensive medications in the obese populations. Unfortunately, it is an old
article.
Current literature on this topic is very limited (Table 2). Two of the larger, more complete
studies, one a randomized controlled trial by Nedogoda et al., and the other being a systemic review by
Owen and Reisin shed light on this topic and have been referenced numerous times. Outside of the
studies outlined in Table 2, not many have assessed antihypertensive medications as it pertains to
prescribing and cost, from an electronic health record such as the Health Facts Database. This is one
reason that this study is unique. As demonstrated in Table 2, current literature focuses on determining
which medications are most appropriate and/or effective in obese patients, and treatment of
hypertension in obesity.
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Table 2. Relevant Current Literature
Article Title
Population

Authors
Owen & Reisin

Landsberg et al.

Nedogoda et al.

Schmieder et al.

Anti-hypertensive Drug Treatment of
Patients with and the Metabolic
Syndrome and Obesity: A Review of
Evidence, Meta-Analysis, Post hoc and
Guidelines Publications
Obesity‐Related Hypertension:
Pathogenesis, Cardiovascular Risk, and
Treatment
Randomized Trial of Perindopril,
Enalapril, Losartan and Telmisartan in
Overweight or Obese Patients with
Hypertension
Obesity as a Determinant for Response
to Antihypertensive Treatment.

Year Published

ad hoc studies, prospective
studies, and guideline
publications

2015

N/A

2013

120 overweight or obese
patients (body mass index
≥27 kg/m2) with hypertension

2013

N/A

1993

Chapter 3
Methodology
The purpose of this section is to detail the methods performed and steps taken to complete this
research project. In this section, the reader can expect to find in-depth statements on the research
design, the research population, as well as their demographics and how this population was chosen, indepth explanations on how data was collected, any collection instruments employed as well as their
development process, and lastly, an explanation of data analysis. This chapter will be concluded with a
summary of everything discussed.
Research Design
This study used information entered into Cerner’s Health Facts Library. This library contains a
plethora of de-identified patient information and allowed for the analysis of the study question.
Population and Sample Design
The purpose of this study was to make inferences on the prescribing of antihypertension
medications in an obese population via frequency of occurrences in the database, as well as the
associated cost of these medications. With such a question, the population must meet specific
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requirements. This study employed an obese population with multiple comorbid conditions. Patients
were retrospectively selected based on records from Cerner’s Health Facts Database. Those selected
had a BMI of 30 or greater, were 18 years or older, and had to have a clinical diagnosis of hypertension.
Patients also had to be on at least one prescription antihypertensive medication. Patients were
excluded if they had a diagnosis of obesity, but no history of hypertension, had a diagnosis of
hypertension but no prescription antihypertensive medications, or had an BMI greater than 70. This BMI
cutoff was based on the National Institute of Health’s BMI chart that includes BMIs through 60. While a
BMI greater than 70 is not uncommon, BMIs that high are more prone to charting errors. This
population was selected because they provided the most relevant characteristics for the question at
hand. This population would allow for answering of the question as well as further analysis of any postanalysis questions. Patient demographic breakdown is included in Table 3.

Table 3. Patient Demographics
Age & BMI

Race and Ethnicity (n=39,844)

Average Age

59

Caucasian

90.8%

Most Common Age

67

African American

5.4%

Average BMI

34

Asian

0.065%

Most Common BMI

30.7

Pacific Islander

0.005%

Native American

3.1%

Gender
Male

41.1%

Asian/Pacific Islander

0.07%

Female

58.8%

Other/Unknown/Not Mapped

0.51%
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Data Collection
Data for this study was collected retrospectively via Cerner’s Health Facts Database. Structured
Query Language (SQL) was used to design tables that incorporated all relevant and necessary
information. The final table included age, total charges (the cost for the encounter, which includes
covered and non-covered charges), BMI, year, patient sk (a unique blinded person identifier),
medication brand and generic names, and drug classification. Information from this table allowed for
the identification of hypertensive medications.
Data Collection Instrument
Cerner’s Health Facts Database was employed for the purposes of data collection in this study.
Structured Query Language was used to create queries and tables that contained all relevant and
necessary information
Results
This purpose of this chapter is to discusses the results of this study as well as the generalizability
of said results.
In this study, angiotensin converting enzyme (ACE) inhibitors were identified as the most
common antihypertensive medication prescribed (it occurred the most often) to this obese population.
According to data released from the Department of Pharmaceutical Sciences within the College of
Pharmacy at Larkin University in conjunction with the Centers for Disease Control and Prevention
Institute, it is also the most common blood pressure lowering medication prescribed to non-obese
populations as well (Figure 1).
The average age of this population was 59, with an average BMI of 34, classifying this population
as obesity class 1. When all ACE inhibitors were examined, lisinopril (Prinivil®, Zestril®) occurred the
most often. This insinuates that, in this population, lisinopril was prescribed the most often. Other ACE
14
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inhibitors included enalapril, accupril, and captopril. When cost of each agent was assessed, the total
charges was highest when associated with lisinopril. Because lisinopril is prescribed more than other
ACE inhibitors, it has a greater chance of being associated with a more expensive encounter, when
compared to other similar medications. We do not believe that the addition of lisinopril contributes to a
more expensive encounter. This hypothesis is consistent with what was seen when unit price was
analyzed. When unit price was assessed, lisinopril was the cheapest, on average (Table 6).
When the results of this study was compared to The American College of Cardiology and
American Heart Association (ACC/AHA) Hypertension Treatment Guidelines, it appears that the study
population received appropriate and evidence based care. These guidelines are used nationally and
internationally and set the standards for care of patients with hypertension. They recommend the use of
an ACE inhibitor, calcium channel blocker, thiazide diuretic, or angiotensin receptor blocker first line. As
mentioned earlier, ACE inhibitors were the most common antihypertensive in our population. When
combination first line agents were assessed the following in Table 4 was observed.

Table 4. Combination First Line Antihypertensive Agents
ACE-I + Thiazide

ACE-I + CCB

20%

12%

Most Commonly Prescribed Anti-Hypertensive In US (2018)
1. Lisinopril (ACE-I)
7. Amlodipine (CCB)
11. Hydrochlorothiazide (Thiazide)
12. Losartan (ARB)
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Figure 1. Top 40 Most Commonly Prescribed Drugs in the United States

Table 6. Unit Price of ACE Inhibitors
ACE

Unit Price ($)

Accupril

5.52

Captopril

0.87-8

Enalapril

5-12.75

Prinivil

3-6

Lisinopril

0.8-13.65

Chapter 5
Conclusions and Recommendations
This chapter will reiterate the purpose of the study as well as highlight important points and
connect supporting arguments.
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Conclusions
The results of this study, mentioned above, found that the ACE inhibitor lisinopril was the most
commonly prescribed antihypertensive in the study populations. This is what is also seen outside of the
study population in the real world. In fact, lisinopril was the most commonly prescribed medication in
the United States in 2018 (Figure 1). ACE inhibitors were likely the most prescribed agent due to the
numerous benefits outside of blood pressure lowering. In fact, in addition to lowering blood pressure,
they also help protect the kidneys, decrease the risk of heart attack, decrease the risk of stroke,
decrease all-cause mortality by 10% and decrease cardiovascular mortality by 12%. Additionally, for
individuals who have had a previous heart attack or stroke, ACE inhibitors have been shown to decrease
reoccurrence. Why lisinopril in particular was the most commonly occurring ACE inhibitor is likely due to
cost. When unit price was analyzed, it was cheapest for lisinopril (Table 6). However, this same analysis,
when applied to the other ACE inhibitors, didn’t hold true; number of occurrences wasn’t positively
correlated with cost. There are likely other underlying factors that are at play and further analysis is
warranted to determine this lack of correlation. Considering the results and the conclusion, it does not
appear that hypertension medications are contributing much to the overall healthcare expenditure. It
should also be noted, however, that this information is a snapshot in time. Therapy progression and
adverse effects that led to medication discontinuation, among other things, is unknown. It is important
to keep this in mind when definitively determining therapy appropriateness.
Recommendations
ACE inhibitors are a class of antihypertensive medications that offer a range of benefits outside
of lowering blood pressure. They are currently some of the most commonly prescribed blood pressure
lowering medications. Based on the results and conclusions of this study, ACE inhibitors are being
prescribed preferentially to other similar medications and should continue to be prescribed as such,
given the cost and aforementioned benefits.
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Future studies should examine prescribing of DM and HLD medications in the obese with a
similar focus of this study. This is timely and appropriate as there have been surges in the price of
insulin, used to treat DM, in recent months. Additionally, cost should be assed based on region of the
country. It has been well established that the south has higher rates of obesity than the west and
northeast. Other areas of interest can focus on determining formulary status and figuring out how
formulary designations affect guideline prescribing.
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